Forex Haberleri

U.S. Dollar Down As Soft Inflation Data Supports Rate Cut Hopes

The U.S. dollar was lower against its major counterparts in the New York session on Friday, as the Federal Reserve's preferred measure of inflation slowed more than expected in November, reinforcing expectations that the Federal Reserve will begin cutting interest rates in March.
RTTNews | 614 gün önce
U.S. Consumer Sentiment Improves More Than Previously Estimated In December

U.S. Consumer Sentiment Improves More Than Previously Estimated In December

Revised data released by the University of Michigan on Friday showed consumer sentiment in the U.S. improved by slightly more than initially estimated in the month of December. The University of Michigan said its consumer sentiment index for December was upwardly revised to 69.7 from a preliminary reading of 69.4. Economists had expected the index to be unrevised.
RTTNews | 614 gün önce
U.S. New Home Sales Unexpectedly Plunge To One-Year Low In November

U.S. New Home Sales Unexpectedly Plunge To One-Year Low In November

New home sales in the U.S. unexpectedly saw a substantial decrease in the month of November, according to a report released by the Commerce Department on Friday. The report said new home sales plummeted by 12.2 percent to an annual rate of 590,000 in November after tumbling by 4.0 percent to a revised rate of 672,000 in October.
RTTNews | 614 gün önce
Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
RTTNews | 614 gün önce
U.S. Consumer Price Growth Slows More Than Expected In November

U.S. Consumer Price Growth Slows More Than Expected In November

A highly anticipated report released by the Commerce Department on Friday showed consumer price growth in the U.S. slowed by more than expected in the month of November. The report said the annual rate of consumer price growth decelerated to 2.6 percent in November from a downwardly revised 2.9 percent in October.
RTTNews | 614 gün önce
more news
Decline In UK GDP Signals Recession

Decline In UK GDP Signals Recession

The UK economic output contracted in the third quarter indicating that the economy is moving into a mild recession towards the end of the year. Gross domestic product shrank 0.1 percent sequentially in the third quarter, which was revised down from the flat growth estimated initially, the Office for National Statistics reported Friday.
RTTNews | 614 gün önce
Dollar Mixed Ahead Of U.S. Personal Income And Spending Data

Dollar Mixed Ahead Of U.S. Personal Income And Spending Data

U.S. personal income and spending data and durable goods orders for November are due at 8:30 am ET Friday. Ahead of these data, the greenback traded mixed against its major rivals. While it fell against the euro and the yen, it held steady against the pound and the franc.
RTTNews | 614 gün önce
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash

Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash

Bristol-Myers Squibb Co. (BMY) and biopharmaceutical company Karuna Therapeutics, Inc. (KRTX) announced Friday that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
RTTNews | 614 gün önce
Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash

Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash

Biopharmaceutical company Theseus Pharmaceuticals, Inc. (THRX) announced Friday it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire Theseus for a price per share of Theseus common stock of between $3.90 and $4.05 in cash.
RTTNews | 614 gün önce

Stay up to date!

Add Haberler to your browser

Extension Picture